The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
In: International Journal of COPD, Jg. ume 11 (2016-08-01), S. 2041-2053
Online
academicJournal
Zugriff:
Marc Miravitlles,1 Kenneth R Chapman,2 Ferran Chuecos,3 Anna Ribera,4 Esther Garcia Gil3 1Department of Pneumology, Vall d’Hebron University Hospital, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Asthma & Airway Centre, University Health Network, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada; 3Global Medicines Development, AstraZeneca PLC, Barcelona, Spain; 4Global Medical Affairs, AstraZeneca PLC, Barcelona, Spain Background: Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of life. This pooled analysis of two Phase III studies assessed the impact of aclidinium/formoterol on patients with COPD categorized by symptom status.Methods: Data were pooled from two 24-week, randomized, placebo-controlled studies of twice-daily aclidinium/formoterol 400/12 µg in moderate-to-severe COPD (ACLIFORM [NCT01462942] and AUGMENT [NCT01437397]). These post hoc analyses evaluated the efficacy of aclidinium/formoterol versus placebo or monotherapies in patients defined as less/more symptomatic by a) Evaluating Respiratory Symptoms (E-RS™) score ≥10/
| Titel: |
The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
|
|---|---|
| Autor/in / Beteiligte Person: | Miravitlles, M ; Chapman, KR ; Chuecos, F ; Ribera, A ; Garcia Gil, E |
| Link: | |
| Zeitschrift: | International Journal of COPD, Jg. ume 11 (2016-08-01), S. 2041-2053 |
| Veröffentlichung: | Dove Medical Press, 2016 |
| Medientyp: | academicJournal |
| ISSN: | 1178-2005 (print) |
| Schlagwort: |
|
| Sonstiges: |
|